Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Clinical trials sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd., explained in plain language.
-
New immunotherapy combo aims to tackle tough lung cancer
Disease control OngoingThis early-stage trial tests an experimental drug called SHR-1316, given as a shot under the skin, together with standard chemotherapy (carboplatin and etoposide) in people with extensive-stage small cell lung cancer who have not had prior treatment. The study looks at how the dr…
Phase: PHASE1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New cocktail of drugs shows promise for bile duct cancer
Disease control OngoingThis study tests a new drug combination for people with advanced biliary tract cancer (bile duct cancer) who haven't had treatment before. About 93 participants will receive either a standard chemotherapy plus two immunotherapy drugs, or the same plus an extra experimental drug. …
Phase: PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Lung cancer combo trial pulled before starting
Disease control TerminatedThis study was designed to test a new combination of drugs for people with advanced non-small cell lung cancer. The goal was to see if the treatment was safe and could shrink tumors. However, the trial was withdrawn before any participants were enrolled, so no results are availab…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New hope for EGFR lung cancer: experimental drug SHR-A2009 takes on chemo in phase 3 trial
Disease control OngoingThis Phase 3 study compares a new experimental drug, SHR-A2009, to standard chemotherapy in 498 people with advanced EGFR-mutated non-small cell lung cancer whose current targeted therapy (EGFR TKI) has stopped working. The goal is to see if SHR-A2009 can better control the cance…
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New immunotherapy cocktail targets Hard-to-Treat cancers
Disease control OngoingThis Phase 2 trial tests whether adding an experimental immunotherapy drug (SHR-8068) to a standard immunotherapy (adebrelimab) plus chemotherapy can shrink tumors better than standard treatment alone in people with advanced stomach or esophageal cancer. About 153 participants wi…
Phase: PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 13:05 UTC